Prot # V212-001: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)

Project: Research project

Project Details

Effective start/end date7/1/116/20/18


  • Clinical Financial Services, LLC (Prot # V212-001 // Prot # V212-001)
  • Merck Sharp & Dohme Corporation (Prot # V212-001 // Prot # V212-001)